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Review
Preparation Methods and Clinical Outcomes
of Platelet-Rich Plasma for Intra-articular
Hip Disorders
A Systematic Review and Meta-analysis
of Randomized Clinical Trials
Flávio Luı́s Garcia,*†‡ MD, PhD, Brady T. Williams,* MD, Evan M. Polce,* BS, Daniel B. Heller,* BA,
Zachary S. Aman,§ BA, Benedict U. Nwachukwu,k MD, MBA, Shane J. Nho,*{ MD, MS,
and Jorge Chahla,*{# MD, PhD
Investigation performed at the Section of Young Adult Hip Surgery, Division of Sports Medicine,
Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA
Background: Despite its increasing use in the management of musculoskeletal conditions, questions remain regarding the
preparation methods of platelet-rich plasma (PRP) and its clinical applications for intra-articular hip disorders, including femoro-
acetabular impingement syndrome (FAIS), labral pathology, and osteoarthritis (OA).
Purpose: To systematically review and assess the preparation methods and clinical outcomes from randomized clinical trials
(RCTs) on the use of PRP for intra-articular hip disorders.
Study Design: Systematic review; Level of evidence, 2.
Methods: A systematic review in accordance with the 2009 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines was performed in September 2019. The Cochrane Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials, PubMed, Ovid Medline, and Embase were queried for studies regarding the use of PRP to treat intra-
articular hip disorders. Qualifying articles were English-language RCTs describing the use of PRP for intra-articular hip disorders,
either as standalone treatment or surgical augmentation. Two authors independently assessed article eligibility. Data pertaining to
patient characteristics, indication for treatment, PRP preparation method, follow-up period, and clinical outcomes were extracted.
Study results were qualitatively reported and quantitatively compared using meta-analysis when appropriate.
Results: Seven RCTs met inclusion criteria. Four studies described the use of PRP for hip OA and 3 utilized PRP at arthroscopy for
FAIS and labral tears. Outcomes after PRP for OA demonstrated improvement in validated patient-reported outcome measures for
up to 1 year; however, pooled effect sizes found no statistically significant difference between PRP and hyaluronic acid (HA)
regarding pain visual analog scale scores at short-term (2 months; P ¼ .27), midterm (4-6 months; P ¼ .85), or long-term (1 year;
P¼ .42) follow-up. When injected at arthroscopy, 1 study reported improved outcomes, 1 reported no difference in outcomes, and
1 reported worse outcomes compared with controls. The meta-analysis demonstrated no statistically significant difference on the
modified Harris Hip Score (mHHS) between PRP and control cohorts at a minimum 1-year follow-up. There were considerable
deficiencies and heterogeneity in the reporting of PRP preparation methods for both indications.
Conclusion: Treatment of OA with PRP demonstrated reductions in pain and improved patient-reported outcomes for up to 1 year.
However, there was no statistically significant difference between PRP and HA in pain reduction. Likewise, for FAIS and labral
surgery there was no statistically significant difference in mHHS outcomes between patients treated with PRP and controls. Given
the limited number of studies and variability in PRP preparations, additional high-quality randomized trials are warranted.
Keywords: platelet-rich plasma; osteoarthritis; hip arthroscopy; femoroacetabular impingement; outcomes
Intra-articular hip pathologies, notably osteoarthritis (OA)
and femoroacetabular impingement syndrome (FAIS), rep-
resent a major cause of disability and pain for many
patients and a substantial economic burden on society.32
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This has led to increased interest in disease-modifying
and hip joint preservation treatments, such as orthobio-
logics, over the past few decades. News coverage and
media reporting of outcomes after orthobiologic treat-
ments in elite athletes have also drawn considerable
attention, further increasing the demand for these ther-
apies and potentially generating unrealistic patient
expectations.2
Platelet-rich plasma (PRP) is one of the most commonly
used orthobiologics. The term “PRP” broadly describes
autologous preparations of peripheral blood that have
undergone centrifugation to increase the platelet concen-
tration; however, the other constituents can be quite vari-
able, including the concentration of leukocytes.7 The
clinical use of PRP aims to promote tissue regeneration
through the effects of growth factors and cytokines released
by activated platelets24 and has been described for the
treatment of a wide spectrum of musculoskeletal condi-
tions, such as acute muscle injuries,21,43 degenera-
tive6,10,18,26,28,45 and traumatic9 cartilage lesions,
meniscal disorders,5,39 ligamentous injuries,5,19,36,40 rota-
tor cuff injuries,20,46 plantar fasciitis,31 lateral epicondyli-
tis,34,38 and other tendinopathies.16 Likewise, PRP has
been increasingly used to treat a variety of hip disorders,
either alone or as an augmentation for hip arthroscopic
procedures.8,13,41,42
Despite its increased utilization in the treatment of
intra-articular hip disorders, the efficacy of PRP on the
treatment of these pathologies has not been completely
elucidated, and its use remains controversial. Further-
more, the influence of composition on the regenerative
characteristics of PRP has yet to be determined.30,35 The
primary purpose of this systematic review was to examine
and provide a comprehensive review of the evidence from
randomized clinical trials (RCTs) on PRP preparation
methods for the treatment of intra-articular hip patholo-
gies, including FAIS, labral pathology, and OA and clinical
outcomes. The secondary aim of this review was to
describe the range of PRP preparation methods. Corre-
spondingly, it was hypothesized that there would be con-
siderable heterogeneity in the reporting of PRP
preparation methods, and that there would be a signifi-
cant benefit in patients who received PRP injections, as
indicated by statistically significant differences in patient-
reported outcomes.
METHODS
Article Identification and Selection
A systematic review of PRP application for the treatment of
intra-articular hip disorders was conducted in accordance
with the 2009 PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) guidelines. A compre-
hensive literature search was performed using the Cochrane
Database of Systematic Reviews, the Cochrane Central Reg-
ister of Controlled Trials, PubMed (1980 to present), Medline
(1980 to present), and Embase (1980 to present). Queries
were performed and screened between September and
November 2019. The following Boolean search terms were
used: “platelet rich plasma” AND (“hip arthroscopy” OR “hip
pathology” OR “femoroacetabular impingement” OR
“osteoarthritis” OR “biomechanics”). The systematic review
protocol was registered with the PROSPERO prospective
registrar of systematic reviews (No. CRD42020159802).
Inclusion criteria were English-language literature and
randomized clinical studies reporting on the use of PRP for
intra-articular hip disorders, either as a standalone treat-
ment or as an augmentation for arthroscopic hip proce-
dures. Publications were excluded if they involved the
treatment of extra-articular hip disorders, tendon and/or
muscle injection of PRP, animal studies, or nonrandomized
studies, or did not include at least 1 patient-reported out-
come. There was no minimum duration of follow-up that
was required for inclusion.
Two investigators (F.L.G. and D.B.H.) independently
reviewed the abstracts from all identified articles. If neces-
sary, full-text articles were reviewed to appropriately iden-
tify articles for inclusion. Additionally, reference lists from
the included studies were reviewed to verify that all eligible
articles were considered.
Data Extraction
Data were extracted from the full text of all eligible articles
using standardized data collection forms and included
patient characteristics, indication for treatment, PRP prep-
aration method, control group and treatment (eg, placebo,
hyaluronic acid [HA], and corticosteroid), follow-up period,
and clinical outcomes. For continuous variables, the means,
standard deviations, and ranges were collected when
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reported. Data were recorded into a custom spreadsheet
using a modified information extraction table.23
Assessment of Methodological Quality
The methodologic quality of each included study was
assessed with the Coleman Methodology Score (CMS).11
The CMS is a 10-item questionnaire scored from 0 to 100
points that has been used in the rating of RCTs22 and is
based on the CONSORT (Consolidated Standards of
Reporting Trials) statement.1 A perfect score of 100 points
represents a study design that largely avoids the influence
of chance, biases, and confounding factors.11
Statistical Analysis
A series of meta-analyses were conducted for outcomes
reported in at least 3 studies. The meta-analyses were per-
formed using a random-effects model with inverse variance
for data pooling and weighting. Forest plots were con-
structed for visual presentation of the results from individ-
ual studies and pooled summary estimates. A P value <.05
was considered statistically significant. Study heterogene-
ity was assessed through I2 tests. All statistical analyses
were performed using Review Manager 5 (Version 5.3; The
Nordic Cochrane Center).44
For the variables that did not meet the aforementioned
criteria (reported in a minimum of 3 studies), a meta-
analysis was considered methodologically inappropriate,
and the data were qualitatively synthesized and reported
in both narrative fashion and table format. Extracted data




The literature search identified 1701 studies through the
initial database query. After duplicates and non-English
titles were removed, 711 articles were screened, with 7 arti-
cles3,13-15,29,41,42 ultimately meeting the inclusion criteria
(Figure 1). The mean CMS for the 7 studies assessed in this
review was 87.2 (range, 83-93).
Four studies3,13-15 described the use of PRP for hip OA
treatment, and 3 studies29,41,42 reported on PRP augmen-
tation at the time of arthroscopic FAIS and labral surgery.
The weighted mean age was 45.3 years (range, 34.6-72.5
years), and the weighted mean number of PRP injections
per patient was 1.9 (range, 1-3 injections). Detailed study
characteristics are reported in Table 1.
PRP Preparation and Processing Protocols
Among the included studies, there was heterogeneity in
PRP preparation and processing protocols. The initial
whole blood volume, centrifugation rate, and duration
were reported in 5 studies3,13-15,42 (71.4%). For the first
centrifugation, the median rate was 1500 rpm (range,
1480-3100 rpm) and the median duration was 6 minutes
(range, 5-15 minutes). For the second centrifugation, the
median rate was 3400 rpm (range, 3100-3500 rpm) and the
median duration was 12.5 minutes (range, 9-15 minutes).
The mean whole blood volume extracted was 94.8 mL
(range, 8-150 mL). The volume of PRP injected into each
hip joint was reported in all studies, with a mean injected
PRP volume of 4.9 mL (range, 3-7 mL). The mean PRP
platelet concentration after preparation was reported in 3
studies3,14,42 with a mean platelet concentration 3.8 times
greater than that of whole blood (range, 2-7 times).
An exogenous activation method used to induce platelet
degranulation and release of growth factors and cytokines
into the PRP solution was reported in 3 studies
(42.9%).3,13,41 Two studies used 10% calcium chloride,3,13
and 1 study used an undisclosed exogenous activator.41
Three studies14,15,29 (42.9%) did not mention whether an
activator was used, and 1 study42 (14.3%) specifically
reported not using an activator. Detailed PRP preparation
information is reported in Table 2.
PRP for OA Treatment
There were 4 studies3,13-15 that evaluated outcomes after
intra-articular injection of PRP for the management of OA
Figure 1. PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) flowchart showing application
of the selection criteria to the studies identified with the
search strategy.
The Orthopaedic Journal of Sports Medicine PRP for Hip Disorders 3
(Tables 1 and 3). All 4 studies, a total of 334 patients, com-
pared the efficacy of PRP with that of hyaluronic acid (HA).
The severity of symptomatic hip OA included across the
studies varied considerably, ranging from grade 0 to grade
4 according to the Kellgren-Lawrence (KL) classification.27
Battaglia et al3 and Dallari etal13 reported improvement in
pain visual analog scale (VAS) from pretreatment to short-
term (up to 2 months) and midterm (between 4 and 6 months)
follow-up time points. Di Sante et al14 reported improvement
in VAS from pretreatment to short-term follow-up, but not at
the midterm follow-up. Doria et al15 did not evaluate patients
at the short-term follow-up but reported improvement in the
VAS from pretreatment to midterm and long-term
(12 months) follow-ups. In 2 studies,3,13 the VAS at the
long-term follow-up demonstrated increased pain compared
with the short-term follow-up; however, these were still sig-
nificantly improved compared withpretreatmentpain scores.
The remaining 2 studies did not allow such temporal compar-
ison because the VAS was not assessed at either the short-
term15 or long-term14 follow-up.
Three studies3,13,15 evaluated patients with the Harris
Hip Score (HHS). Both Battaglia et al3 and Doria et al15
demonstrated statistically significant improvements in
HHS after treatment. In contrast, Dallari et al did not find
any significant improvement in HHS in either group. How-
ever, none of the studies reported statistically significant
differences between control and treatment groups for post-
treatment changes in HHS.
Three studies13-15 evaluated patients with the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) questionnaire. Dallari et al13 reported signifi-
cantly greater improvement in the WOMAC scores from
pretreatment to short-term and midterm follow-ups for the
PRP-treated group, but a loss of statistical significance
compared with HA and PRP þ HA at the long-term
follow-up. Di Sante et al14 evaluated patients only at
short-term and midterm follow-ups and found no statisti-
cally significant difference in the WOMAC scores before
and after PRP treatment, while HA treatment resulted in
statistically significant improvements in WOMAC scores at
4 weeks; however, these results were not sustained at
16 weeks. Finally, Doria et al15 evaluated the patients only
at midterm and long-term follow-ups, reporting improve-
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PRP for OA treatment
Battaglia
(2013)3









injections; 2 wk apart)
1, 3, 6, and 12
mo
89
Dallari (2016)13 OA K-L grades 1-4/
US-guided injections
111 (PRP group:
44; PRP þ HA
group: 31; HA
group: 36)
NR (18-65) 3 intra-articular
injections
(1 wk apart)
a. PRP þ HA
b. HA (3 intra-articular
injections; 1 wk apart)
2, 6, and 12 mo 93
Di Sante
(2016)14
OA K-L grades 2-3/
US-guided injections
43 (PRP group: 21;
HA group: 22)




injections; 1 wk apart)
1 and 4 mo 84
Doria (2017)15 OA K-L grades 0-2/
US-guided injections
80 (PRP group: 40;
HA group: 40)




injections; 1 wk apart)
6 and 12 mo 83
PRP augmentation for FAIS and labral surgery
Redmond
(2015)42

















injection at the end of
surgery)
3 and 24 mo 86
LaFrance
(2015)29





35 (PRP group: 20;
normal saline
group: 15)






injection at the end of
surgery)
1, 3, 6, and 12
mo
83




57 (PRP group: 30;
no injection
group: 27)




No injection 2 d; 3, 6, and 24
mo
93
aFAIS, femoroacetabular impingement syndrome; HA, hyaluronic acid; K-L, Kellgren-Lawrence classification; NR: not reported; OA,
osteoarthritis; PRP, platelet-rich plasma; US, ultrasound.
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however, no statistically significant difference was found
between the PRP- and HA-treated groups (Table 3).
A meta-analysis was performed, and the pooled effect
sizes showed no statistically significant difference between
PRP and HA in terms of pain reduction as determined by
the VAS, either at the short-term (P ¼ .27), midterm (P ¼
.85), or long-term (P ¼ .42) follow-up (Figure 2). Heteroge-
neity, as evaluated by I2 tests, demonstrated values of 62%,
90%, and 77% at the short-, mid-, and long-term follow-ups,
respectively.
PRP Augmentation for FAIS and Labral Surgery
Three studies29,41,42 evaluated the efficacy of PRP injection
as an augmentation for FAIS and labral surgery (Tables 1
and 4). Arthroscopic labral repair plus femoral osteochon-
droplasty was performed in 92 hips, and arthroscopic labral
repair or debridement with or without acetabuloplasty,
femoroplasty, microfracture, and/or capsular repair was
done on 271 hips.
LaFrance et al29 compared the efficacy of PRP with that
of 0.9% normal saline injection. The authors described
improvement in all patient-reported outcome measures
throughout the study period; however, no statistically sig-
nificant difference between the groups was observed.
Rafols et al41 compared PRP injection and no injection.
The authors found some differences in outcomes between
the groups, with the PRP group reporting lower VAS scores
only on the second day after surgery and a lower incidence
of joint effusion at the 6-month follow-up. All other out-
comes showed no statistically significant differences
between the groups.
Redmond et al42 evaluated the efficacy of PRP injection
compared with bupivacaine injection. Surgeries included
either labral repair or labral debridement, as well as other
intra-articular procedures, including acetabuloplasty,
femoroplasty, microfracture, and capsular repair. The
authors reported that the PRP group demonstrated a lower
mean modified HHS (mHHS) and a higher VAS score than
the bupivacaine group 2 years after surgery (Table 4), but
the reason for these findings could not be identified.
A meta-analysis was performed, and the pooled effect
sizes showed no statistically significant difference between
PRP and controls for mHHS at a minimum 12-month
follow-up (P ¼ .25) (Figure 3). Heterogeneity was assessed
with I2 tests, with a calculated value of 13%.
DISCUSSION
The most important finding of this investigation was the
absence of statistically significant differences between
PRP, HA, and combined therapies in the treatment of hip
OA. The treatment of hip OA with PRP accounted for the
majority of relevant publications, representing 57.1% of
RCTs identified by this systematic review. In this patient
population, PRP injection resulted in improvements in both
pain and select patient-reported outcome measures for up
to 1 year after injection. However, meta-analysis and
pooled effect sizes demonstrated no statistically significant
difference between PRP- and HA-treated groups in terms of
pain reduction, as determined by the VAS, for up to 1 year
after injection in patients with hip OA.
Although the pain reduction and improvements in
patient-reported outcome measures may last for up to
12 months after PRP injection for hip OA, this effect was
most evident in the first 4 to 6 months after treatment and
seemed to decrease after that period.3,13 Systematic
reviews and meta-analyses of RCTs have similarly reported
TABLE 2
PRP Preparation and Composition Data for the Included Studiesa













PRP for OA treatment
Battaglia
(2013)3
2-spin method (1800 rpm for 15 min
þ 3500 rpm for 10 min)
150 5 7 baseline 10% calcium
chloride
P3-x-A
Dallari (2016)13 2-spin method (1480 rpm for 6 min
þ 3400 rpm for 15 min)





2-spin method (3100 rpm for 9 min
þ 3100 rpm for 9 min)
8 3 2 baseline NR P2-NA-B
Doria (2017)15 2-spin method (1480 rpm for 6 min
þ 3400 rpm for 15 min)
150 5 NR NR NA-NA-NA
PRP augmentation for FAIS and labral surgery
Redmond
(2015)42





NR 5 NR NR P3-NA-Aa
Rafols (2015)41 GPS III System (Biomet Biologics) NR 6 NR Yes
(undisclosed)
P4-x-Aa
aFAIS, femoroacetabular impingement syndrome; NR, not reported; OA, osteoarthritis; PAW, platelets, activation, and white cells; PRP,
platelet-rich plasma.
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that PRP can reduce pain and improve functional status in
patients affected by knee OA.12,33,45 However, indications
and results from knee OA treatment with PRP cannot be
immediately extrapolated to the hip, since cartilage char-
acteristics and biomechanics are disparate among
joints.4,17,37
In addition, PRP is increasingly being used as augmen-
tation for hip arthroscopy8,13,41,42; however, the relevant
literature is still limited and controversial. In this review,
3 such studies met inclusion criteria. Rafols et al41 reported
lower postoperative pain scores at 48 hours and fewer joint
effusions at 6 months in patients receiving PRP at the time
of arthroscopic FAIS and labral surgery. Conversely,
LaFrance et al29 compared the efficacy of PRP with that
of a 0.9% normal saline injection and reported that PRP
injection did not improve the clinical outcomes up to 1 year
postoperatively in patients undergoing arthroscopic FAIS
and labral surgery. Finally, Redmond et al42 compared the
efficacy of PRP with that of bupivacaine injection for
arthroscopic FAIS and labral surgery and reported that the
PRP group had higher pain scores and lower mHHS than
the bupivacaine group 2 years after surgery. Pooled effect
sizes from the meta-analysis demonstrated no statistically
significant difference in mHHS between patients treated
with PRP and the controls, with a minimum follow-up of
1 year.
Other noteworthy findings include the heterogeneity of
PRP preparation methods and the considerable deficiencies
in the reporting of preparation-related factors and basic
attributes of PRP preparations. Similar to the systematic
review performed by Chahla et al,7 the current study found
no consensus in the timing or number of injections needed,
nor agreement on the formulation or standardized report-
ing methodology of processing. This variability in the prep-
aration and resultant end product may influence the
reported outcomes; therefore, it is important to interpret
the results in light of a potentially heterogeneous PRP
product and deficiencies in reporting. In order to improve
the reporting and ultimately the ability to assess the impact
of PRP treatment, reported metrics should include, at a
minimum, the starting volume, anticoagulant utilized,
detailed preparation technique (including spin rate and/or
gravitational forces and number of separate centrifuge
events), make and model of centrifuge, use of activating
agents, and final concentrations of platelets, nucleated
cells, and red blood cells.7
It should be noted that evaluating the patient-reported
outcomes after PRP augmentation for arthroscopic hip sur-
gery may be challenging. It is well-documented that statis-
tically significant changes in patient-reported outcome
instruments may in fact have little clinical significance.25
Additionally, it is difficult for these studies to differentiate
between the clinical impact of PRP alone and the clinical
impact of the PRP plus the associated arthroscopic
techniques, which in 1 study42 included labral repair or
labral debridement with or without acetabuloplasty, femor-
oplasty, microfracture, and/or capsular repair. These con-
comitant procedures may confound analysis and the
identification of any clinical benefit directly attributable
to the PRP injection. In addition to pathology-specific
TABLE 3














PRP 5.47 3.72 4.29 4.75
HA 5.97 3.58 4.04 4.59
HHS
PRP 58.11 73.72 70.23 65.73
HA 62.90 78.02 75.79 72.55
Dallari (2016)13
VAS
PRP — 2.3 2.1 2.4
HA — 3.8 4.4 4.2
PRP þ HA — 3.5 3.5 3.8
WOMAC
PRP — 73 72 —
HA — 59 59 —
PRP þ HA — 59 59 —
HHS
PRP — — — —
HA — — — —
PRP þ HA — — — —
Di Sante (2016)14
VAS NR
PRP 7.08 4.73 6.36
HA 6.32 5.27 3.63
WOMAC–pain NR
PRP 58.8 44.2 53.4
HA 42.3 29.6 19.9
WOMAC–stiffness NR
PRP 53.7 46.4 47.2




PRP 59.8 49.1 50.8
HA 45.8 39.1 28.3
Doria (2017)15
VAS
PRP 7.5 NR 6.3 6.4
HA 7.8 NR 6.3 6.1
WOMAC–pain
PRP 23.7 NR 7.8 7.4
HA 24 NR 9.7 9
WOMAC–stiffness
PRP 3.8 NR 2.1 2
HA 4.3 NR 3.1 3.1
WOMAC–physical
function
PRP 29.4 NR 12.3 12
HA 28.5 NR 11.3 10.9
HHS
PRP 64 NR 75 78
HA 62 NR 74 75
aHA, hyaluronic acid; HHS, Harris Hip Score; NR, not reported;
PRP, platelet-rich plasma; VAS, visual analog scale (scaled to 0-
10); WOMAC, Western Ontario and McMaster Universities Oste-
oarthritis Index; —, data were reported as box plot graphs only.
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outcome scores, there is a need for sensitive and specific
objective outcome tools and advanced imaging modalities
to enable the accurate assessment of outcomes for muscu-
loskeletal conditions.
The results of this study must be interpreted in the
context of the following limitations. First, no attempt was
made to correlate PRP preparation methods with the
patient-reported outcomes. Such evaluation is currently
confounded by the different time points used in individual
studies, as well as the deficiencies in the reporting of PRP
preparation methods and composition characteristics.
Second, although there is high-quality evidence suggest-
ing that the use of PRP is associated with the
improvement of select patient-reported outcome mea-
sures, the use of different outcome instruments in the
included RCTs did not allow for a quantitative effect esti-
mate to be calculated. With the exception of the VAS for
OA and the mHHS for FAIS and labral surgery patients,
the results presented are largely qualitative. Further-
more, the strength of this systematic review was limited
by the available literature, including both articles that
were identified for inclusion and those that were poten-
tially omitted or missed during the query. For example,
search terms did not specifically include “labrum” or
“labral,” which may have resulted in the potential omis-
sion of relevant studies. In the articles that were identified
Figure 2. Forest plot depicting visual analog scale (VAS) score summary estimate (center of the diamond) and 95% CI (width of
diamond) comparing platelet-rich plasma (PRP) and hyaluronic acid (HA) injections for hip osteoarthritis at the short-term (up to 2
months), midterm (between 4 and 6 months), and long-term (1 year) follow-ups. Means and SDs are reported for the VAS scale. IV,
inverse variance.
Figure 3. Forest plot depicting modified Harris Hip Score (mHHS) summary estimate (center of the diamond) and 95% CI (width of
diamond) comparing platelet-rich plasma (PRP) and controls for femoroacetabular impingement syndrome and labral surgery with
a minimum 12-month follow-up. Means and SDs are reported in points on the mHHS scale. IV, inverse variance.
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for inclusion, the descriptions of PRP preparation proto-
cols in clinical studies were inconsistent, and a large pro-
portion of the studies did not provide sufficient
information to allow the protocol to be reproduced. The
current reporting of PRP preparation and composition
does not enable comparison of the PRP products being
delivered to patients. Last, the data describing the role
of PRP as augmentation for hip arthroscopy are unclear,
with a limited number of studies and controversial results,
requiring additional high-quality RCTs.
CONCLUSION
The treatment of OA with PRP demonstrated reductions
in pain and improved patient-reported outcomes for up to
1 year. However, there was no statistically significant dif-
ference between PRP and HA in terms of pain reduction.
Likewise, for FAIS and labral surgery, there was no statis-
tically significant difference in mHHS between patients
treated with PRP and controls. Given the limited number
of studies and variability in PRP preparations, additional
high-quality randomized trials are warranted.
REFERENCES
1. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT state-
ment for reporting randomized trials: explanation and elaboration.
Ann Intern Med. 2001;134(8):663-694.
2. Andia I, Maffulli N. A contemporary view of platelet-rich plasma ther-
apies: moving toward refined clinical protocols and precise indica-
tions. Regen Med. 2018;13(6):717-728.
3. Battaglia M, Guaraldi F, Vannini F, et al. Efficacy of ultrasound-guided
intra-articular injections of platelet-rich plasma versus hyaluronic acid
for hip osteoarthritis. Orthopedics. 2013;36(12):e1501-e1508.
4. Bedi A, Kelly BT. Femoroacetabular impingement. J Bone Joint Surg
Am. 2013;95(1):82-92.
5. Braun HJ, Wasterlain AS, Dragoo JL. The use of PRP in ligament and
meniscal healing. Sports Med Arthrosc Rev. 2013;21(4):206-212.
6. Campbell KA, Saltzman BM, Mascarenhas R, et al. Does intra-
articular platelet-rich plasma injection provide clinically superior out-
comes compared with other therapies in the treatment of knee
osteoarthritis? A systematic review of overlapping meta-analyses.
Arthroscopy. 2015;31(11):2213-2221.
7. Chahla J, Cinque ME, Piuzzi NS, et al. A call for standardization in
platelet-rich plasma preparation protocols and composition reporting:
a systematic review of the clinical orthopaedic literature. J Bone Joint
Surg Am. 2017;99(20):1769-1779.
8. Chahla J, LaPrade RF, Mardones R, et al. Biological therapies for
cartilage lesions in the hip: a new horizon. Orthopedics. 2016;39(4):
e715-e723.
9. Chahla J, Stone J, Mandelbaum BR. How to manage cartilage inju-
ries? Arthroscopy. 2019;35(10):2771-2773.
10. Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic acid versus
platelet-rich plasma: a prospective, double-blind randomized con-
trolled trial comparing clinical outcomes and effects on intra-
articular biology for the treatment of knee osteoarthritis. Am J Sports
Med. 2017;45(2):339-346.
11. Coleman BD, Khan KM, Maffulli N, Cook JL, Wark JD. Studies of
surgical outcome after patellar tendinopathy: clinical significance of
methodological deficiencies and guidelines for future studies. Victo-
rian Institute of Sport Tendon Study Group. Scand J Med Sci Sports.
2000;10(1):2-11.
TABLE 4
Patient-Reported Outcome Scores for PRP Augmentation for Femoroacetabular Impingement Syndrome and Labral Surgerya
Author (Year) Outcome Score Group Pretreatment Short-term FU Midterm FU Long-term FU Extended FU
LaFrance (2015)29 mHHS PRP 51.9 66.6 78.4 75.9
NRNormal saline 50.3 59.6 83.4 81.3
HOS-ADL PRP 59.1 68.4 79.6 84.1
Normal saline 55.7 58.9 88.3 85.0
HOS-SS PRP 35.1 31.6 61.7 65.4
Normal saline 29.2 20.2 75.6 75.2
NAHS PRP 54.9 66.3 81.3 82.0
Normal saline 52.6 59.1 87.6 80.9
Rafols (2015)41 VAS PRP 5.04 3.04 0.71 NR NR
No PRP 4.94 5.20 0.77
mHHS PRP 70.79 NR 94.80 NR 97.10
No PRP 71.48 94.00 94.76
Redmond (2015)42 VAS PRP 5.64 NR 2.62 NR 3.36
BUP 5.44 2.58 2.52
mHHS PRP 62.77 82.09 78.58
BUP 64.40 80.93 82.63
HOS-ADL PRP 64.49 81.63 79.77
BUP 66.43 83.66 83.57
HOS-SS PRP 41.31 61.43 67.47
BUP 43.52 61.83 69.08
NAHS PRP 58.02 76.62 78.34
BUP 61.30 77.65 81.27
aPosttreatment scores are divided into short-term (up to 2 months postop), midterm (3-6 months postop), long-term (12 months postop),
and extended (24 months postop) follow-up time points. BUP, bupivacaine; FU, follow-up; HOS-ADL, Hip Outcome Score Activities of Daily
Living subscale; HOS-SS, Hip Outcome Score Sport-Specific subscale; mHHS, modified Harris Hip Score; NAHS: Non-Arthritic Hip Score;
NR, not reported; PRP, platelet-rich plasma; VAS, visual analog scale.
8 Garcia et al The Orthopaedic Journal of Sports Medicine
12. Dai WL, Zhou AG, Zhang H, Zhang J. Efficacy of platelet-rich plasma
in the treatment of knee osteoarthritis: a meta-analysis of randomized
controlled trials. Arthroscopy. 2017;33(3):659-670.
13. Dallari D, Stagni C, Rani N, et al. Ultrasound-guided injection of
platelet-rich plasma and hyaluronic acid, separately and in combina-
tion, for hip osteoarthritis. Am J Sports Med. 2016;44(3):664-671.
14. Di Sante L, Villani C, Santilli V, et al. Intra-articular hyaluronic acid vs
platelet-rich plasma in the treatment of hip osteoarthritis. Med Ultra-
son. 2016;18(4):463-468.
15. Doria C, Mosele GR, Caggiari G, Puddu L, Ciurlia E. Treatment of early
hip osteoarthritis: ultrasound-guided platelet rich plasma versus hya-
luronic acid injections in a randomized clinical trial. Joints. 2017;5(3):
152-155.
16. Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-rich plasma
as a treatment for patellar tendinopathy: a double-blind, randomized
controlled trial. Am J Sports Med. 2014;42(3):610-618.
17. El Bitar YF, Lindner D, Jackson TJ, Domb BG. Joint-preserving sur-
gical options for management of chondral injuries of the hip. J Am
Acad Orthop Surg. 2014;22(1):46-56.
18. Filardo G, Di Matteo B, Di Martino A, et al. Platelet-rich plasma intra-
articular knee injections show no superiority versus viscosupplemen-
tation: a randomized controlled trial. Am J Sports Med. 2015;43(7):
1575-1582.
19. Fleming BC, Proffen BL, Vavken P, Shalvoy MR, Machan JT, Murray
MM. Increased platelet concentration does not improve functional
graft healing in bio-enhanced ACL reconstruction. Knee Surg Sports
Traumatol Arthrosc. 2015;23(4):1161-1170.
20. Gwinner C, Gerhardt C, Haneveld H, Scheibel M. Two-staged appli-
cation of PRP in arthroscopic rotator cuff repair: a matched-pair anal-
ysis. Arch Orthop Trauma Surg. 2016;136(8):1165-1171.
21. Hamilton B, Tol JL, Almusa E, et al. Platelet-rich plasma does not
enhance return to play in hamstring injuries: a randomised controlled
trial. Br J Sports Med. 2015;49(14):943-950.
22. Harris JD, Erickson BJ, Abrams GD, et al. Methodologic quality of
knee articular cartilage studies. Arthroscopy. 2013;29(7):1243-1252.
23. Harris JD, Quatman CE, Manring MM, Siston RA, Flanigan DC. How
to write a systematic review. Am J Sports Med. 2014;42(11):
2761-2768.
24. Hsu WK, Mishra A, Rodeo SR, et al. Platelet-rich plasma in orthopae-
dic applications: evidence-based recommendations for treatment.
J Am Acad Orthop Surg. 2013;21(12):739-748.
25. Jaeschke R, Singer J, Guyatt GH. Measurement of health status.
Ascertaining the minimal clinically important difference. Control Clin
Trials. 1989;10(4):407-415.
26. Koh YG, Kwon OR, Kim YS, Choi YJ. Comparative outcomes of open-
wedge high tibial osteotomy with platelet-rich plasma alone or in
combination with mesenchymal stem cell treatment: a prospective
study. Arthroscopy. 2014;30(11):1453-1460.
27. Kohn MD, Sassoon AA, Fernando ND. Classifications in brief:
Kellgren-Lawrence classification of osteoarthritis. Clin Orthop Relat
Res. 2016;474(8):1886-1893.
28. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-
articular injection versus hyaluronic acid viscosupplementation as
treatments for cartilage pathology: from early degeneration to osteo-
arthritis. Arthroscopy. 2011;27(11):1490-1501.
29. LaFrance R, Kenney R, Giordano B, Mohr K, Cabrera J, Snibbe J. The
effect of platelet enriched plasma on clinical outcomes in patients
with femoroacetabular impingement following arthroscopic labral
repair and femoral neck osteoplasty. J Hip Preserv Surg. 2015;2(2):
158-163.
30. LaPrade RF, Goodrich LR, Phillips J. Use of platelet-rich plasma
immediately after an injury did not improve ligament healing, and
increasing platelet concentrations was detrimental in an in vivo animal
model. Am J Sports Med. 2018;46(3):702-712.
31. Martinelli N, Marinozzi A, Carnı̀ S, Trovato U, Bianchi A, Denaro V.
Platelet-rich plasma injections for chronic plantar fasciitis. Int Orthop.
2013;37(5):839-842.
32. Mather RC III, Nho SJ, Federer A, et al. Effects of arthroscopy for
femoroacetabular impingement syndrome on quality of life and eco-
nomic outcomes. Am J Sports Med. 2018;46(5):1205-1213.
33. Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD.
Efficacy of intra-articular platelet-rich plasma injections in knee
osteoarthritis: a systematic review. Arthroscopy. 2016;32(3):
495-505.
34. Merolla G, Dellabiancia F, Ricci A, et al. Arthroscopic debridement
versus platelet-rich plasma injection: a prospective, randomized,
comparative study of chronic lateral epicondylitis with a nearly
2-year follow-up. Arthroscopy. 2017;33(7):1320-1329.
35. Murray IR, LaPrade RF. Platelet-rich plasma: renewed scientific
understanding must guide appropriate use. Bone Joint Res. 2016;
5(3):92-94.
36. Murray MM, Palmer M, Abreu E, Spindler KP, Zurakowski D, Fleming
BC. Platelet-rich plasma alone is not sufficient to enhance suture
repair of the ACL in skeletally immature animals: an in vivo study.
J Orthop Res. 2009;27(5):639-645.
37. Novakofski KD, Berg LC, Bronzini I, et al. Joint-dependent response
to impact and implications for post-traumatic osteoarthritis. Osteoar-
thritis Cartilage. 2015;23(7):1130-1137.
38. Palacio EP, Schiavetti RR, Kanematsu M, Ikeda TM, Mizobuchi RR,
Galbiatti JA. Effects of platelet-rich plasma on lateral epicondylitis of
the elbow: prospective randomized controlled trial. Rev Bras Ortop.
2016;51(1):90-95.
39. Pujol N, Salle De Chou E, Boisrenoult P, Beaufils P. Platelet-rich
plasma for open meniscal repair in young patients: any benefit? Knee
Surg Sports Traumatol Arthrosc. 2015;23(1):51-58.
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